TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21831004

Group type: EXPERIMENTAL
Intervention: Group-based high intensity exercise training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 19058679

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Primer applied gently (inactive) + Clearfil Protect Bond
Number of subjects: 40

Group type: COMPARATOR
Intervention: 38% phosphoric acid for 15 s, rinsed 15 s, and dried 15 s + Clearfil Protect Primer applied gently (inactive) + Clearfil Protect Bond
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Primer applied with agitation by microapplicator brush (active) + Clearfil Protect Bond
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 38% phosphoric acid for 15 s, rinsed 15 s, and dried 15 s + Clearfil Protect Primer applied with agitation by microapplicator brush (active) + Clearfil Protect Bond
Number of subjects: 40
Study: 16871129

Group type: EXPERIMENTAL
Intervention: MAS XR 20 mg/day
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: MAS XR 40 mg/day
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: MAS XR 60 mg/day
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: MAS XR (all doses)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 14668006

Group type: EXPERIMENTAL
Intervention: 50 mg of mifepristone every 2 weeks for 24 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 24 weeks
Number of subjects: 20
Study: 10952230

Group type: EXPERIMENTAL
Intervention: CA 15.3
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: TPA
Number of subjects: 192
Study: 9395376

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 6 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 12 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 23
Study: 8236464

Group type: EXPERIMENTAL
Intervention: Proguanil daily (PROG)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Chloroquine once weekly (CQ)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combination of Chloroquine and Proguanil (CQ+PROG)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Maternal titres vs cord titres
Number of subjects: 203

Group type: COMPARATOR
Intervention: Caesarean section or placenta weight between 0.75 and 1 kg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Cord titres at birth
Number of subjects: 203
Study: 3891642

Group type: EXPERIMENTAL
Intervention: Salbutamol plus beclomethasone dipropionate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 30
Study: 29540410

Group type: EXPERIMENTAL
Intervention: Patella mobilisation therapy (PMT) with three manual mobilisation sessions and home-based vastus medialis oblique muscle exercise at 2-month intervals
Number of subjects: 208

Group type: COMPARATOR
Intervention: Waiting list control group receiving usual care
Number of subjects: 208
Study: 26695005

Group type: EXPERIMENTAL
Intervention: Patient Empowerment training sessions
Number of subjects: 589
Study: 24763929

Group type: EXPERIMENTAL
Intervention: VR exercises that challenged balance (eg, soccer goaltending, snowboarding) performed while standing
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exposure to identical VR environments but whose games did not challenge balance (performed in sitting)
Number of subjects: 59
Study: 22568118

Group type: EXPERIMENTAL
Intervention: TAU plus bBTi (4 weekly 1-hour individual sessions)
Number of subjects: 37
Study: 19768767

Group type: EXPERIMENTAL
Intervention: Q-Sweat
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mayo-QSART
Number of subjects: 94
Study: 17233546

Group type: EXPERIMENTAL
Intervention: Osteoporosis medications (e.g., Bisphosphonates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies to increase adherence (e.g., reducing administration frequency, monitoring patients, providing instructions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-adherence factors (e.g., adverse effects, pain, uncertainty about BMD test results)
Number of subjects: 0
Study: 15618034

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 200

Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 200
Study: 12449520

Group type: EXPERIMENTAL
Intervention: Early feeding of low‐residue diets 6 h post‐operatively (n = 95)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Traditional dietary management of clear liquids once normal bowel sounds were heard (n = 87)
Number of subjects: 182
Study: 10458007

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 7872931

Group type: EXPERIMENTAL
Intervention: Implicit memory (tachistoscopic identification)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Explicit memory (recognition)
Number of subjects: 32
Study: 2222172

Group type: EXPERIMENTAL
Intervention: Protocol groups using supranormal cardiac index, oxygen delivery, and oxygen consumption values as goals
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control groups using normal values as therapeutic goals
Number of subjects: 2
Study: 240481

Group type: EXPERIMENTAL
Intervention: Practolol (200 mg twice daily)
Number of subjects: 3038
Study: 31810418

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV) in thiomersal-containing multi-dose vial (MDV) format
Number of subjects: 302

Group type: COMPARATOR
Intervention: Licensed thiomersal-free pre-filled syringe (PFS) format
Number of subjects: 302
Study: 30467686

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel + Cilostazol
Number of subjects: 334
Study: 28854085

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 25925203

Group type: EXPERIMENTAL
Intervention: IV amino acid therapy (up to 100 g daily)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 474
Study: 23948391

Group type: EXPERIMENTAL
Intervention: overnight storage with alkaline peroxide-based cleansing tablet
Number of subjects: 51

Group type: COMPARATOR
Intervention: dry storage
Number of subjects: 51

Group type: COMPARATOR
Intervention: overnight storage in water
Number of subjects: 51
Study: 21273617

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (repeated every 3 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus vinorelbine (repeated every 3 or 4 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel (repeated every 4 weeks)
Number of subjects: 61
Study: 19758415

Group type: EXPERIMENTAL
Intervention: James' blinding index (BI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bang's BI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16446400

Group type: EXPERIMENTAL
Intervention: Blood pressure changes during the video game task
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: Blood pressure changes during the star tracing task
Number of subjects: 2816
Study: 15451900

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (premeal inhaled insulin plus a bedtime dose of Ultralente)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Subcutaneous insulin (at least two daily injections of mixed regular/NPH insulin)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 299
Study: 11054332

Group type: EXPERIMENTAL
Intervention: INTACS (KeraVision, Inc.)
Number of subjects: 165
Study: 9229982

Group type: EXPERIMENTAL
Intervention: Minimal-flow anaesthesia with desflurane (0.5 l/min fresh gas flow)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-flow anaesthesia with desflurane (1.0 l/min fresh gas flow)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: High-flow phase with desflurane (4.4 l/min fresh gas flow)
Number of subjects: 106
Study: 8153919

Group type: EXPERIMENTAL
Intervention: 200 mmol/day slow sodium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3524549

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prostaglandin F2 alpha in Tylose gel
Number of subjects: 82
Study: 29447780

Group type: EXPERIMENTAL
Intervention: Nonprimary PCI at hospitals without cardiac surgery on-site (SoS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective PCI at an SoS hospital
Number of subjects: 0
Study: 26511939

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µgm
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin 5 IU
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbetocin and Oxytocin
Number of subjects: 100
Study: 24453500

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment at 42°C for 120 seconds to the dorsal root ganglion (DRG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group (needle placement)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 32
Study: 22840612

Group type: EXPERIMENTAL
Intervention: The Little Prince is Depressed (LPD) programme, a 12-week school-based face-to-face programme with psycho-educational lessons and homework assignments.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 20495521

Group type: EXPERIMENTAL
Intervention: Medina classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movahed classification
Number of subjects: 0
Study: 18341520

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 169
Study: 15701498

Group type: EXPERIMENTAL
Intervention: Videoconference lectures
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 110
Study: 12190752

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.2‐0.4 micro g.kg‐1.min‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl bolus (3 micro g.kg‐1) + propofol infusion (2 mg.kg‐1.h‐1)
Number of subjects: 50
Study: 10598608

Group type: EXPERIMENTAL
Intervention: COPA with a millimeter microchip sensor
Number of subjects: 20

Group type: COMPARATOR
Intervention: COPA with a fiberoptic scope
Number of subjects: 20
Study: 8583804

Group type: EXPERIMENTAL
Intervention: Neodymium:yttrium aluminum garnet contact laser surgery (n = 33)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Stapled lung reduction surgery (n = 39)
Number of subjects: 72
Study: 1902363

Group type: EXPERIMENTAL
Intervention: Water bed
Number of subjects: 6

Group type: COMPARATOR
Intervention: King's Fund bed
Number of subjects: 6
Study: 6211167

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine methonitrate (2 mg) as a wet aerosol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and terbutaline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and terbutaline combination
Number of subjects: 10
Study: 30927859

Group type: EXPERIMENTAL
Intervention: Numerical simulations using a mathematical model of glycolytic oscillations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Log-normal distribution of the maximum uptake velocity of glucose and four randomized rate constants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity of GLUT
Number of subjects: 0
Study: 28183466

Group type: EXPERIMENTAL
Intervention: Novel self-expanding TAV bioprosthesis
Number of subjects: 241
Study: 26049076

Group type: EXPERIMENTAL
Intervention: Sentence-combining (SC) intervention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Narrative-based (NAR) intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 52
Study: 23813620

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg single dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg multiple doses
Number of subjects: 30
Study: 21645394

Group type: EXPERIMENTAL
Intervention: Early participants
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Late participants
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 1668
Study: 19192836

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray) with double the application time of the primer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AdheSE (Ivoclar‐Vivadent) with double the application time of the primer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Futurabond NR (Voco) with double the application time of the primer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: One Up Bond F Plus (J Morita) with double the application time of the primer
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control application time of the primer for all adhesive systems
Number of subjects: 32
Study: 17081163

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg twice daily for 3 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15579757

Group type: COMPARATOR
Intervention: Rosiglitazone (4 or 8 mg/d) for 26 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosiglitazone for 52 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glyburide for 52 weeks
Number of subjects: 0
Study: 11716833

Group type: EXPERIMENTAL
Intervention: Negative feedback presented in the left visual field (LVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback presented in the right visual field (RVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback stimuli were faces (smiling or frowning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback stimuli were colored squares
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback stimuli were verbal feedback
Number of subjects: 0
Study: 9422013

Group type: EXPERIMENTAL
Intervention: Transcervical resection of the endometrium (n = 93)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Medical treatments (n = 94)
Number of subjects: 197
Study: 8101550

Group type: EXPERIMENTAL
Intervention: HIV-immune plasma (250 mL every 4 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: HIV antibody-negative plasma (250 mL every 4 weeks)
Number of subjects: 63
Study: 3552925

Group type: EXPERIMENTAL
Intervention: Prednisolone therapy (28-day course)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31099272

Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 213

Group type: COMPARATOR
Intervention: Supported employment program (sub-group)
Number of subjects: 213
Study: 30141288

Group type: EXPERIMENTAL
Intervention: EMG guided point injection at Renying (ST 9), administered three times a week for 2 weeks, in addition to conventional drugs and rehabilitation training.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional drugs combined with rehabilitation training, administered once daily for 2 weeks.
Number of subjects: 60
Study: 27573938

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25648350

Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham Adaptation (SA)
Number of subjects: 70
Study: 23512320

Group type: EXPERIMENTAL
Intervention: Daily self-weighing intervention using smart scales and e-mail
Number of subjects: 91
Study: 20924617

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam-ketamine
Number of subjects: 50
Study: 18219456

Group type: EXPERIMENTAL
Intervention: Gout prescription I
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Gout prescription II
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Gout prescription III
Number of subjects: 107

Group type: COMPARATOR
Intervention: Indomethacin and Benzobromarone (control)
Number of subjects: 107
Study: 16173861

Group type: EXPERIMENTAL
Intervention: PrimeTime intervention targeting child competencies
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lunch Buddy intervention targeting peer ecology
Number of subjects: 86
Study: 12823646

Group type: EXPERIMENTAL
Intervention: Warfarin 1.25 mg + Aspirin 75 mg daily (W/A)
Number of subjects: 668

Group type: COMPARATOR
Intervention: No anticoagulation (C)
Number of subjects: 668
Study: 11905682

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using serum prostate specific antigen measurement, followed by transrectal ultrasound scanning and biopsy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy, radical radiotherapy, and monitoring with treatment if required.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future developments in diagnostic testing, molecular markers of progression, and early chemoprevention.
Number of subjects: 0
Study: 9001835

Group type: EXPERIMENTAL
Intervention: N-acetyl-D-glucosamine (NAG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polymeric N-acetyl-D-glucosamine (POLY-Nag)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NAG and POLY-Nag
Number of subjects: 10
Study: 1464336

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both metoprolol and placebo (inability to perform predischarge stress testing)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both metoprolol and placebo (low predischarge exercise capacity)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ST segment shift > or = 1 mm
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Administration of metoprolol
Number of subjects: 190
Study: 6143964

Group type: EXPERIMENTAL
Intervention: RIT 4237 vaccine
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 31486253

Group type: EXPERIMENTAL
Intervention: Low-dose tramadol (0.5 mg/kg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Meperidine (0.5 mg/kg and 0.75 mg/kg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 mcg/kg and 0.75 mcg/kg)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 350
Study: 29502373

Group type: EXPERIMENTAL
Intervention: Postoperative precision nutrition treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Traditional postoperative nutrition treatment
Number of subjects: 71
Study: 26902132

Group type: EXPERIMENTAL
Intervention: SVV monitoring
Number of subjects: 90

Group type: COMPARATOR
Intervention: CVP monitoring
Number of subjects: 90
Study: 25251377

Group type: EXPERIMENTAL
Intervention: Zeaxanthin only (20 mg/day; n=29)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mixed formulation (26 mg/day zeaxanthin, 8 mg/day lutein, and 190 mg/day mixed omega‐3 fatty acids; n=25)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 92
Study: 23158830

Group type: EXPERIMENTAL
Intervention: DE-PLAN, a structured educational intervention program focused on changing healthy lifestyles (diet and physical activity)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Usual care for the prevention and treatment of DM2 currently provided in Osakidetza
Number of subjects: 1089
Study: 21061788

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 159)
Number of subjects: 288

Group type: COMPARATOR
Intervention: conventional surgery or exclusive radiotherapy (CONV arm; n = 129)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm)
Number of subjects: 288

Group type: COMPARATOR
Intervention: conventional surgery or exclusive radiotherapy (CONV arm)
Number of subjects: 288
Study: 17922895

Group type: EXPERIMENTAL
Intervention: r-hGH administered by cool.click 2
Number of subjects: 38

Group type: COMPARATOR
Intervention: r-hGH administered by needle and syringe
Number of subjects: 38
Study: 16320942

Group type: EXPERIMENTAL
Intervention: Test sustained-release indapamide formulation (3 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference sustained-release indapamide formulation (3 mg)
Number of subjects: 20
Study: 11880565

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (ferrous sulfate 300 mg/tablet)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (ferrous sulfate 300 mg/tablet)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 9460148

Group type: EXPERIMENTAL
Intervention: Act-as-usual group (encouraged to continue normal activities)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Soft neck collar group (given time off from work and immobilized)
Number of subjects: 201
Study: 7649495

Group type: EXPERIMENTAL
Intervention: Allopurinol (200 mg during induction of anesthesia and 100 mg after starting extracorporeal circulation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no allopurinol)
Number of subjects: 22
Study: 2669552

Group type: EXPERIMENTAL
Intervention: Immunotherapy with dog or cat extract (n = 14), subcutaneous injections with alum-adsorbed depot extract (Alutard-SQ), maintenance dose of 100,000 SQ-U or maximum tolerated dose.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional medical therapy (n = 13).
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Immunotherapy with dog or cat extract (n = 14).
Number of subjects: 27
Study: 4455095

Group type: EXPERIMENTAL
Intervention: Training on a two choice simultaneous visual discrimination task with brightness or shape as the relevant dimension.
Number of subjects: 0